These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38456678)

  • 1. Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: Trans-Atlantic Pancreatic Surgery (TAPS) Consortium study.
    Theijse RT; Stoop TF; Janssen QP; Prakash LR; Katz MHG; Doppenberg D; Tzeng CD; Wei AC; Zureikat AH; Groot Koerkamp B; Besselink MG
    Br J Surg; 2024 Mar; 111(3):. PubMed ID: 38456678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
    Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
    van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
    JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
    Suker M; Beumer BR; Sadot E; Marthey L; Faris JE; Mellon EA; El-Rayes BF; Wang-Gillam A; Lacy J; Hosein PJ; Moorcraft SY; Conroy T; Hohla F; Allen P; Taieb J; Hong TS; Shridhar R; Chau I; van Eijck CH; Koerkamp BG
    Lancet Oncol; 2016 Jun; 17(6):801-810. PubMed ID: 27160474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
    Janssen QP; van Dam JL; Doppenberg D; Prakash LR; van Eijck CHJ; Jarnagin WR; O' Reilly EM; Paniccia A; Besselink MG; Katz MHG; Tzeng CD; Wei AC; Zureikat AH; Groot Koerkamp B;
    J Natl Cancer Inst; 2022 May; 114(5):695-703. PubMed ID: 35157075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
    Ghaneh P; Palmer D; Cicconi S; Jackson R; Halloran CM; Rawcliffe C; Sripadam R; Mukherjee S; Soonawalla Z; Wadsley J; Al-Mukhtar A; Dickson E; Graham J; Jiao L; Wasan HS; Tait IS; Prachalias A; Ross P; Valle JW; O'Reilly DA; Al-Sarireh B; Gwynne S; Ahmed I; Connolly K; Yim KL; Cunningham D; Armstrong T; Archer C; Roberts K; Ma YT; Springfeld C; Tjaden C; Hackert T; Büchler MW; Neoptolemos JP;
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):157-168. PubMed ID: 36521500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy.
    Lee M; Kang JS; Kim H; Kwon W; Lee SH; Ryu JK; Kim YT; Oh DY; Chie EK; Jang JY
    J Hepatobiliary Pancreat Sci; 2023 Jan; 30(1):111-121. PubMed ID: 34581022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
    Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM
    BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen.
    Garnier J; Ewald J; Marchese U; Gilabert M; Moureau-Zabotto L; Giovannini M; Poizat F; Delpero JR; Turrini O
    Eur J Surg Oncol; 2020 Aug; 46(8):1510-1515. PubMed ID: 32146053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study.
    Suker M; Nuyttens JJ; Groot Koerkamp B; Eskens FALM; van Eijck CHJ
    J Surg Oncol; 2018 Nov; 118(6):1021-1026. PubMed ID: 30259526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
    Blazer M; Wu C; Goldberg RM; Phillips G; Schmidt C; Muscarella P; Wuthrick E; Williams TM; Reardon J; Ellison EC; Bloomston M; Bekaii-Saab T
    Ann Surg Oncol; 2015 Apr; 22(4):1153-9. PubMed ID: 25358667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based Study to Assess Subsequent Surgical Resection and Overall Survival.
    Dai WF; Habbous S; Saluja R; Beca JM; Raphael M; Arias J; Gavura S; Earle CC; Biagi JJ; Coburn N; Chan KKW
    Clin Oncol (R Coll Radiol); 2023 May; 35(5):e303-e311. PubMed ID: 36863956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX.
    Choi YH; Lee SH; You MS; Shin BS; Paik WH; Ryu JK; Kim YT; Kwon W; Jang JY; Kim SW
    Gut Liver; 2021 Mar; 15(2):315-323. PubMed ID: 32235008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort.
    Kourie H; Auclin E; Cunha AS; Gaujoux S; Bruzzi M; Sauvanet A; Lourenco N; Trouilloud I; Louafi S; El-Hajjar A; Vaillant JC; Smith D; Touchefeu Y; Bachet JB; Pietrasz D; Taieb J
    Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):663-668. PubMed ID: 31029644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
    Pouypoudat C; Buscail E; Cossin S; Cassinotto C; Terrebonne E; Blanc JF; Smith D; Marty M; Dupin C; Laurent C; Dabernat S; Chiche L; Vendrely V
    Dig Liver Dis; 2019 Jul; 51(7):1043-1049. PubMed ID: 31000479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer.
    Byun Y; Han Y; Kang JS; Choi YJ; Kim H; Kwon W; Kim SW; Oh DY; Lee SH; Ryu JK; Kim YT; Jang JY
    J Hepatobiliary Pancreat Sci; 2019 Sep; 26(9):416-425. PubMed ID: 31218836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.